Predictably, in vivo targeting of proteins inhibiting endocytosis such as GOLPH3 or the Na+/H+ exchanger NHE9 represent an attractive therapeutic strategy to limit EGFR oncogenic activity and to increase cancer cell responsiveness to TKI [8,52]. The gene discussed is GOLPH3; the disease is cancer.